Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMS 2023 | Inequality in access to CAR-T therapy in multiple myeloma and the importance of addressing this

Larry Anderson • 28 Sep 2023
IMS 2023
Multiple Myeloma CAR-T

Larry Anderson, MD, PhD, UT Southwestern Medical Center, Dallas, TX, briefly discusses the problem of inequality in access to CAR-T therapy in multiple myeloma, which has been suboptimal due to limited slot availability, and further comments on the need to improve access if these agents are moved into earlier lines of therapy. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Advisory/consultant to BMS, Janssen, Celgene, AbbVie, GSK

More from Larry Anderson

The role of MRD in guiding maintenance treatment decisions in multiple myeloma 1:13
The role of MRD in guiding maintenance treatment decisions in multiple myeloma
Larry Anderson • 19 Sep 2025
The addition of daratumumab to lenalidomide as maintenance therapy in NDMM: the AURIGA trial 4:18
The addition of daratumumab to lenalidomide as maintenance therapy in NDMM: the AURIGA trial
Larry Anderson • 19 Sep 2025
Selecting bridging therapy for patients with myeloma prior to CAR T-cell therapy 1:24
Selecting bridging therapy for patients with myeloma prior to CAR T-cell therapy
Larry Anderson • 27 Sep 2024
Five-year follow-up analysis of KarMMa 2:10
Five-year follow-up analysis of KarMMa
Larry Anderson • 27 Sep 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals